Ann: March 2020 Quarterly Activities and Cash Flow Report, page-3

agreed re prospects of revenue. That's a way off. My issue with being "out" is that we are currently valued at approx. 10% of fair value, and have achieved milestones which should have us at 53% of our drug to market value.
A major shareholder in this company once said to me " I wish I could tell when there is going to be a rerate, but I just never can"
Even if you take off a third for covid, and add it back later, we should still be well into the teens with our share price given what has been achieved.

I am staying in.